SCHEMBL374223

SCHEMBL374223

CCN(CC)CCOc1ccc(N)cc1

nearest known ligand 0.70

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EBP Q15125 1/20 0.62
SIGMAR1 Q99720 1/20 0.62
CYP2D6 P10635 2/20 0.60
CYP1A2 P05177 1/20 0.60
LTA4H P09960 1/20 0.60
CYP2C9 P11712 1/20 0.60
CYP2C19 P33261 1/20 0.60
HTT P42858 1/20 0.60
MCHR1 Q99705 1/20 0.55
TSHR P16473 3/20 0.55
TDP1 Q9NUW8 2/20 0.55
HRH3 Q9Y5N1 2/20 0.54
MAPT P10636 1/20 0.54
CHRNA7 P36544 1/20 0.54
KMT2A Q03164 1/20 0.54
MAOA P21397 1/20 0.54
HTR3A P46098 1/20 0.54
BLM P54132 1/20 0.53
NPSR1 Q6W5P4 1/20 0.53
KDM4E B2RXH2 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL2847620 0.98 EBP (0.60) EBPSIGMAR1CYP2D6CYP1A2LTA4H
Hydrochloric Acid SCHEMBL11838942 0.98 EBP (0.60) EBPSIGMAR1CYP2D6CYP1A2LTA4H
SCHEMBL1283881 0.91 KDM4E (0.58) EBPSIGMAR1CYP2D6CYP1A2LTA4H
SCHEMBL9706125 0.90 EBP (0.72) EBPSIGMAR1CYP2D6CYP1A2LTA4H
SCHEMBL5940250 0.90 EBP (0.51) EBPSIGMAR1CYP2D6CYP1A2LTA4H
Hydrochloric Acid SCHEMBL10425852 0.89 KDM4E (0.57) EBPSIGMAR1TSHRTDP1HRH3
SCHEMBL8790159 0.84 CYP1A2 (0.64) CYP2D6CYP1A2LTA4HCYP2C9CYP2C19
SCHEMBL12156526 0.83 TDP1 (0.50) EBPSIGMAR1CYP2D6CYP1A2LTA4H
SCHEMBL12156464 0.83 CHRNB2 (0.54) EBPSIGMAR1TSHRTDP1HRH3
SCHEMBL3420518 0.82 EBP (0.64) EBPSIGMAR1CYP2D6CYP1A2LTA4H

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 309 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3141552-B1 THIENOPYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE HANMI PHARM IND CO LTD (KR) 2019-04-17 EP claimed
US-10112954-B2 Bicyclic heteroaryl derivatives having inhibitory activity for protein kinase HANMI PHARM. CO., LTD. (KR) 2018-10-30 US claimed
EP-3141552-A1 THIENOPYRIMIDINE DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE Hanmi Pharm. Co., Ltd. (KR) 2017-03-15 EP claimed
EP-2528920-A2 BICYCLIC HETEROARYL DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE Hanmi Pharm. Co., Ltd. (KR) 2012-12-05 EP claimed
US-20120302567-A1 BICYCLIC HETEROARYL DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE KOREA INSTITUTE OF SCIENCE AND TECHNOLOGY (KR) 2012-11-29 US claimed
WO-2011093672-A2 BICYCLIC HETEROARYL DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE HANMI PHARM. CO., LTD. (KR) 2011-08-04 WO claimed
US-20040063686-A1 Carboxamide compounds and their use as antagonists of a human 11cby receptor JOHNSON CHRISTOPHER NORBERT (GB) 2004-04-01 US claimed
EP-1305304-A1 CARBOXAMIDE COMPOUNDS AND THEIR USE AS ANTAGONISTS OF A HUMAN 11CBY RECEPTOR SMITHKLINE BEECHAM PLC (GB) 2003-05-02 EP claimed
WO-2002010146-A1 CARBOXAMIDE COMPOUNDS AND THEIR USE AS ANTAGONISTS OF A HUMAN 11CBY RECEPTOR SMITHKLINE BEECHAM P.L.C. (GB) 2002-02-07 WO claimed
EP-0322643-B1 MEDICINES CONTAINING AS A MIXTURE INTERFERON AND 1-DESOXY-PIPERIDINOSES, PROCESS FOR THEIR MANUFACTURE AND THEIR USE BAYER AG (DE) 1991-07-24 EP claimed
US-12624032-B2 Pyrido[2,3-d]pyrimidin-7-ones and related compounds as inhibitors of protein kinases UNIVERSITY OF HOUSTON SYSTEM (US) 2026-05-12 US disclosed
US-12516055-B2 Protein kinase inhibitors and uses thereof for the treatment of diseases and conditions TRUSTEES OF TUFTS COLLEGE (US) 2026-01-06 US disclosed
EP-4656249-A2 PYRAZOLOPYRIMIDINE DERIVATIVES AS KINASE INHIBITOR Daewoong Pharmaceutical Co., Ltd. (KR) 2025-12-03 EP disclosed
EP-4067354-B1 NOVEL TRIAZOLOPYRIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION COMPRISING SAME DAEWOONG PHARMACEUTICAL CO LTD (KR) 2025-10-22 EP disclosed
EP-4480485-A2 PROTEIN KINASE INHIBITORS AND USES THEREOF FOR THE TREATMENT OF DISEASES AND CONDITIONS University of Houston System (US) 2024-12-25 EP disclosed
US-4588730-A Pyrazolo[3,4,5-k1]acridine compositions and methods for their use as antimicrobials WARNER-LAMBERT COMPANY (US) 1986-05-13 US disclosed
US-4568742-A CATIONIC DYE FOR DYEING PAPER BAYER AKTIENGESELLSCHAFT (DE) 1986-02-04 US disclosed
US-4555572-A Pyrazolo[3,4,5-kl]acridine compositions and methods for their production and use WARNER-LAMBERT COMPANY (US) 1985-11-26 US disclosed
EP-0138302-A1 Pyrazolo(3,4,5-kl)acridine compounds, pharmaceutical compositions comprising the same and processes for their production WARNER-LAMBERT COMPANY (US) 1985-04-24 EP disclosed
US-4503224-A FIBER-REACTIVE, COTTON-POLYESTER BLENDS BAYER AKTIENGESELLSCHAFT (DE) 1985-03-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120302567-A1 BICYCLIC HETEROARYL DERIVATIVES HAVING INHIBITORY ACTIVITY FOR PROTEIN KINASE CDK2, SBK3, CDK2AP1 EBP 1444/4885SIGMAR1 4340/4885CYP2D6 3885/4885
US-10112954-B2 Bicyclic heteroaryl derivatives having inhibitory activity for protein kinase CDK2, SBK3, CDK2AP1 EBP 1444/4885SIGMAR1 4340/4885CYP2D6 3885/4885
US-20040063686-A1 Carboxamide compounds and their use as antagonists of a human 11cby receptor CNR1, GPR3, CCKAR EBP 1703/4885SIGMAR1 99/4885CYP2D6 516/4885
US-12624032-B2 Pyrido[2,3-d]pyrimidin-7-ones and related compounds as inhibitors of protein kinases RIPK2, RIPK1, RIPK4 EBP 2434/4885SIGMAR1 4000/4885CYP2D6 3996/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.